|

Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA

RECRUITINGPhase 4Sponsored by VZW Cardiovascular Research Center Aalst
Actively Recruiting
PhasePhase 4
SponsorVZW Cardiovascular Research Center Aalst
Started2025-07-03
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA). The main questions it aims to answer are: * Do beta-blockers improve coronary blood flow in patients with ANOCA? * Do beta-blockers reduce coronary microvascular resistance in these patients? Researchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation. Participants will: * Receive a beta-blocker or a placebo * Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR \>0.80 and no diameter stenosis \>50%
* Normal, TIMI 3 flow at angiography
* Stable haemodynamics

Exclusion Criteria:

* Clinical signs or symptoms of congestive heart failure
* Severe valvular heart disease requiring either surgical or percutaneous intervention
* History of coronary artery bypass grafting
* Tortuous coronary anatomy in which wire manipulation could be complex
* Heart rate \<60 beats per minute
* Systolic blood pressure \<100 mmHg
* Unable to give consent
* LVEF\<40%

Conditions4

Angina (Stable)Coronary Arterial Disease (CAD)Heart DiseaseMicrovascular Circulation

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.